Immuneering Corporation Operating Expenses
Immuneering Corporation (IMRX) reported Operating Expenses of $19.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- Immuneering Corporation operating expenses for the quarter ending 2026-06-30 was $19.00M, a 28.75% increase year-over-year.
- Immuneering Corporation operating expenses for the quarter ending 2026-03-31 was $15.34M, a 0.97% decline year-over-year.
- Immuneering Corporation operating expenses for the quarter ending 2025-12-31 was $13.75M, a 25.89% decline year-over-year.
- Immuneering Corporation operating expenses for the quarter ending 2025-09-30 was $15.38M, a 0.70% increase year-over-year.
- Immuneering Corporation operating expenses for fiscal 2025 was $59.38M, a 7.33% decline from fiscal 2024.
- Immuneering Corporation operating expenses for fiscal 2024 was $64.07M, a 9.69% increase from fiscal 2023.
- Immuneering Corporation operating expenses for fiscal 2023 was $58.41M, a 12.54% increase from fiscal 2022.
- Immuneering Corporation operating expenses for fiscal 2022 was $51.90M, a 49.09% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.00M 10-Q · filed 2026-08-05 | $34.34M 10-Q · filed 2026-08-05 | $48.09M derived: sum of 3 quarters · filed 2026-08-05 | $63.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $15.34M 10-Q · filed 2026-05-15 | $29.09M derived: sum of 2 quarters · filed 2026-05-15 | $44.47M derived: sum of 3 quarters · filed 2026-05-15 | $59.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $13.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $29.13M derived: sum of 2 quarters · filed 2026-03-06 | $43.89M derived: sum of 3 quarters · filed 2026-08-05 | $59.38M 10-K · filed 2026-03-06 |
| 2025-09-30 | $15.38M 10-Q · filed 2025-11-12 | $30.14M derived: sum of 2 quarters · filed 2026-08-05 | $45.62M 10-Q · filed 2025-11-12 | $64.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $14.76M 10-Q · filed 2026-08-05 | $30.24M 10-Q · filed 2026-08-05 | $48.80M derived: sum of 3 quarters · filed 2026-08-05 | $64.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $15.48M 10-Q · filed 2026-05-15 | $34.04M derived: sum of 2 quarters · filed 2026-05-15 | $49.32M derived: sum of 3 quarters · filed 2026-05-15 | $64.23M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $18.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $33.83M derived: sum of 2 quarters · filed 2026-03-06 | $48.75M derived: sum of 3 quarters · filed 2026-03-06 | $64.07M 10-K · filed 2026-03-06 |
| 2024-09-30 | $15.27M 10-Q · filed 2025-11-12 | $30.19M derived: sum of 2 quarters · filed 2025-11-12 | $45.51M 10-Q · filed 2025-11-12 | $61.82M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $14.91M 10-Q · filed 2025-08-13 | $30.24M 10-Q · filed 2025-08-13 | $46.54M derived: sum of 3 quarters · filed 2025-08-13 | $60.47M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $15.33M 10-Q · filed 2025-05-05 | $31.63M derived: sum of 2 quarters · filed 2025-05-05 | $45.55M derived: sum of 3 quarters · filed 2025-05-05 | $59.06M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $16.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $30.23M derived: sum of 2 quarters · filed 2025-03-20 | $43.73M derived: sum of 3 quarters · filed 2025-03-20 | $58.41M 10-K · filed 2025-03-20 |
| 2023-09-30 | $13.93M 10-Q · filed 2024-11-13 | $27.43M derived: sum of 2 quarters · filed 2024-11-13 | $42.11M 10-Q · filed 2024-11-13 | $56.10M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $13.50M 10-Q · filed 2024-08-06 | $28.18M 10-Q · filed 2024-08-06 | $42.17M derived: sum of 3 quarters · filed 2024-08-06 | $55.38M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $14.68M 10-Q · filed 2024-05-07 | $28.67M derived: sum of 2 quarters · filed 2024-05-07 | $41.87M derived: sum of 3 quarters · filed 2024-05-07 | $53.56M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $13.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $27.19M derived: sum of 2 quarters · filed 2024-03-01 | $38.89M derived: sum of 3 quarters · filed 2024-03-01 | $51.90M 10-K · filed 2024-03-01 |
| 2022-09-30 | $13.21M 10-Q · filed 2023-11-09 | $24.90M derived: sum of 2 quarters · filed 2023-11-09 | $37.92M 10-Q · filed 2023-11-09 | $49.02M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $11.69M 10-Q · filed 2023-08-03 | $24.71M 10-Q · filed 2023-08-03 | $35.81M derived: sum of 3 quarters · filed 2023-08-03 | $44.62M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $13.02M 10-Q · filed 2023-05-04 | $24.12M derived: sum of 2 quarters · filed 2023-05-04 | $32.92M derived: sum of 3 quarters · filed 2023-05-04 | $41.26M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $11.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $19.91M derived: sum of 2 quarters · filed 2023-03-06 | $28.24M derived: sum of 3 quarters · filed 2023-03-06 | $34.81M 10-K · filed 2023-03-06 |
| 2021-09-30 | $8.81M 10-Q · filed 2022-11-10 | $17.14M derived: sum of 2 quarters · filed 2022-11-10 | $23.71M 10-Q · filed 2022-11-10 | $29.74M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $8.33M 10-Q · filed 2022-08-10 | $14.91M 10-Q · filed 2022-08-10 | $20.94M derived: sum of 3 quarters · filed 2022-08-10 | $25.70M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $6.58M 10-Q · filed 2022-05-10 | $12.60M derived: sum of 2 quarters · filed 2022-05-10 | $17.37M derived: sum of 3 quarters · filed 2022-05-10 | $21.22M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $6.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $10.80M derived: sum of 2 quarters · filed 2022-03-10 | $14.65M derived: sum of 3 quarters · filed 2022-03-10 | $18.11M 10-K · filed 2022-03-10 |
| 2020-09-30 | $4.77M 10-Q · filed 2021-11-09 | $8.62M derived: sum of 2 quarters · filed 2021-11-09 | $12.09M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $3.85M 10-Q · filed 2021-09-09 | $7.32M 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |